Ondine Biomedical Inc.

Equities

OBI

CA68234M2058

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. 11:35:05 2024-04-26 am EDT 5-day change 1st Jan Change
5.875 GBX 0.00% Intraday chart for Ondine Biomedical Inc. -12.96% -32.86%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
EARNINGS AND TRADING: Nichols trading in line; Ondine revenue doubles AN
Ondine Biomedical celebrates use of Steriwave in Australian hospital AN
Mater Hospital, to Use Ondine Biomedical's Award-Winning Light-Activated Antimicrobial Technology CI
Ondine Biomedical's Steriwave reduces SSI's by 32%, study shows AN
Ondine Biomedical shares jump as Steriwave approved by HCA Healthcare AN
HCA Healthcare UK Approves the Steriwave Light-Activated Antimicrobial Developed by Ondine Biomedical Inc CI
Ondine says introduction of Steriwave in ICU market could boost sales AN
Ondine Biomedical Inc. Prepares to Enter the Intensive Care Unit Market CI
Ondine Biomedical's Finance Chief Resigns; Interim CFO Named MT
Ondine Biomedical appoints new interim chief financial officer AN
Ondine Biomedical Inc. Announces Executive Appointments CI
Ondine Biomedical Inc. Announces Chief Financial Officer Changes CI
Peel Hunt's RetailBook raises GBP2.5 million AN
Ondine Biomedical Wins First NHS Commercial Deal for Steriwave Treatment MT
Ondine Biomedical Inc. Announces Steriwave Study Shows 77% Drop in Antibody Use CI
Ondine Biomedical says commercial progress ahead of forecast AN
Ondine Biomedical Inc. Announces Steriwave Deploying in Eight New Sites CI
Cindrigo seeks Croatian exploration licence extension AN
Ondine Biomedical Inc. Starts First UK Health Economics Study CI
Ondine Biomedical touts efficacy of Steriwave post presenting research AN
Ondine Biomedical appoints Joseph Errico as new CFO AN
Ondine Biomedical Appoints CFO MT
Ondine Biomedical Inc. Announces Appointment of Joseph P. Errico as Chief Financial Officer CI
Ondine Biomedical fundraise gives nasal photodisinfection tech boost AN
Ondine Biomedical raises GBP2.9 million via placing AN
Chart Ondine Biomedical Inc.
More charts
Ondine Biomedical Inc. is a Canadian life sciences company. The Company is engaged in photodisinfection-based therapies to prevent and treat a range of infections, including those caused by drug-resistant pathogens. Its lead product, Steriwave, is a rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics and other antimicrobials. It also has several products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and the development of topical antiviral therapy for the upper respiratory tract, including the reduction of SARS-CoV-2 titre and transmission.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0588 GBP
Average target price
0.55 GBP
Spread / Average Target
+836.17%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. OBI Stock
  4. News Ondine Biomedical Inc.
  5. Ondine Biomedical Wins First NHS Commercial Deal for Steriwave Treatment